OPKO Health (OPK)
(Delayed Data from NSDQ)
$1.48 USD
-0.11 (-6.92%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.51 +0.03 (2.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
OPK 1.48 -0.11(-6.92%)
Will OPK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OPK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OPK
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down
OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates
OPK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tactile Systems Technology (TCMD) Q2 Earnings and Revenues Surpass Estimates
Why Is OPKO Health (OPK) Up 12.8% Since Last Earnings Report?
OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
Other News for OPK
Greenberg Traurig Advises OPKO Health in $237.5 Million Asset Sale to Labcorp
Opko Health (OPK) Receives a Buy from Piper Sandler
Opko Health’s Strategic Moves and Pipeline Progress Prompt Buy Rating
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Opko Health Subsidiary Restructures with Strategic Sale and Debt Settlement